TRAVERE THERAPEUTICS, INC. (TVTX) Total liabilities 2016–2025
TRAVERE THERAPEUTICS, INC. (TVTX) total liabilities at each fiscal year-end, per SEC filings.
$490.4MFY2025 · since FY2016: $217.5M → $490.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $490.4M | -8.4% |
| FY2024 | $535.0M | -9.0% |
| FY2023 | $588.1M | -6.6% |
| FY2022 | $629.7M | +32.7% |
| FY2021 | $474.5M | +19.8% |
| FY2020 | $396.2M | +3.3% |
| FY2019 | $383.6M | -1.9% |
| FY2018 | $390.9M | +72.0% |
| FY2017 | $227.2M | +4.5% |
| FY2016 | $217.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TVTX financial trends
TVTX RevenueTVTX Net incomeTVTX Net marginTVTX Gross profitTVTX Gross marginTVTX Operating incomeTVTX Operating marginTVTX Operating cash flowTVTX Free cash flowTVTX Capital expendituresTVTX Return on equityTVTX Stock buybacksTVTX Dividends paidTVTX Total assetsTVTX Shareholders’ equityTVTX overview →